MedTrace Logo

Favipiravir in Hospitalized COVID-19 Patients

NCT04359615 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-04-28

No results posted yet for this study

Summary

The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical Education Center and Hospital in Tehran. Patients will be randomly assigned to the two arms of the study and after completing the course of treatment and collecting and analyzing the necessary information from each patient, the results of the study will be published both on this site and in the form of an article in a reputable international journal.

Conditions

Interventions

DRUG

Favipiravir

This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Favipiravir in COVID-19 patients.

DRUG

Hydroxychloroquine

This Drug will be used in all arms as mandated by our governmental guidelines.

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Mohammad Fathi, MD · Shahid Beheshti University of Medical Sciences

  • Sasan Tavana, MD · Shahid Beheshti University of Medical Sciences

  • Nasser Malekpour Alamdari, MD · Shahid Beheshti University of Medical Sciences

  • Mehran Lack, MD · Shahid Beheshti University of Medical Sciences

  • Nader Markazi, MD · Shahid Beheshti University of Medical Sciences

  • Sanaz Zargar Balaye Jam, MD · Shahid Beheshti University of Medical Sciences

  • Seyed Sina Naghibi Irvani, MD, MPH, MBA · Shahid Beheshti University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-20
Primary Completion
2020-05-03
Completion
2020-05-05

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04359615 on ClinicalTrials.gov